Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development
To ignite a life-threatening infection in the body, a virus such as HIV invades body cells by first merging, or fusing, with the cell's outer membrane. Once inside the cell, the invading microbe's genetic material takes over, turning the 'host' cell into a factory to produce more copies of the virus, which then spill out to invade other cells in the body. Scientists had assumed that once a...HIV accessory protein disables host immunity via receptor-protein intermediary
Researchers at the University of Pennsylvania School of Medicine discovered that an HIV-1 accessory protein called Vpr destroys the host cell's ability to survive by binding to a host receptor. This, in turn, keeps an important enzyme from activating the cell's immune system. These findings refine an earlier understanding of Vpr HIV pathogenesis and imply new approaches to treating AIDS, inflamma...Slow Suffocation of Poultry Termed Inhumane
Animal welfare campaigners have termed the plans for slow suffocation of millions of poultry, in the event of a bird flu outbreak as inhumane//. According to Compassion in World Farming (CIWF) the Welfare of Animals (Slaughter and Killing) regulations 1995 have been amended under emergency procedures whereby the Secretary of State has been authorized for "ventilation shutdown" as a meth...Video Game Addiction to Be Termed as a Medical Condition
The American Medical Association will decide later this month whether internet and video game addiction is a real disease. The doctors will vote on the issue at the AMA national meeting at Chicago. The tell tale signs of the new disease is teens holing up in their rooms, ignoring friends, family, even food and a shower, while grades plummet and belligerence soars. Video...Intermediate Hi-Lo® Tracheal Tube
Description:Indications For Usage:...Precut Intermediate Hi-Lo® with Stylet
Description:Indications For Usage:...PARI and Kamada Announce Positive Intermediate Phase I Results for Inhaled Alpha-1 Antitrypsin
MONTEREY, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- Thefirst of two stages of the Phase I clinical trial show positiveresults for Kamada's Alpha-1 Antitrypsin (AAT) liquid drugcandidate for inhalation delivered with PARI's eFlow electronicnebulizer for the treatment of patients suffering from AATdeficiency. Dosage levels studied resulted in good safety profilesand patient tolerabili...